Aktis Oncology, Inc. Common stock Total Liabilities
Aktis Oncology, Inc. Common stock total liabilities. Based on the latest financial reports, Aktis Oncology, Inc. Common stock (AKTS) has total liabilities worth $411.43 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Aktis Oncology, Inc. Common stock's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aktis Oncology, Inc. Common stock (2013–2024)
Total liabilities of Aktis Oncology, Inc. Common stock from 2013 to 2024. This chart illustrates how Aktis Oncology, Inc. Common stock's total liabilities have evolved over time, based on quarterly financial data. Explore AKTS long-term investment intensity to see how much of total assets are deployed in long-term investments.
Aktis Oncology, Inc. Common stock Competitors by Total Liabilities
The table below lists competitors of Aktis Oncology, Inc. Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Diversified United Investment Ltd
AU:DUI
|
Australia | AU$292.18 Million |
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
Mexico | MX$17.92 Billion |
|
Afcon Holdings Ltd
TA:AFHL
|
Israel | ILA1.37 Billion |
|
Hainan Shennong Technology Co Ltd
SHE:300189
|
China | CN¥398.78 Million |
|
Hangzhou Greenda Electronic Materials Co Ltd
SHG:603931
|
China | CN¥179.16 Million |
|
SGSG Science&technology Co Ltd Zhuhai
SHE:300561
|
China | CN¥67.31 Million |
|
Hunan Jiudian Pharmaceutical Co Ltd
SHE:300705
|
China | CN¥1.43 Billion |
|
Latham Group Inc
NASDAQ:SWIM
|
USA | $448.94 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Aktis Oncology, Inc. Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AKTS asset base.
Liquidity & Leverage Metrics
Aktis Oncology, Inc. Common stock Total Liabilities Ratios Explained
Aktis Oncology, Inc. Common stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aktis Oncology, Inc. Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aktis Oncology, Inc. Common stock (2013–2024)
The table below shows the annual total liabilities of Aktis Oncology, Inc. Common stock from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $413.98 Million | +226.40% |
| 2024-06-30 | $126.83 Million | -24.80% |
| 2023-12-31 | $168.66 Million | +169.09% |
| 2023-06-30 | $62.68 Million | -60.22% |
| 2022-12-31 | $157.55 Million | +172.07% |
| 2022-06-30 | $57.91 Million | 0.00% |
| 2021-12-31 | $57.91 Million | +663.55% |
| 2021-06-30 | $7.58 Million | -74.67% |
| 2020-12-31 | $29.94 Million | 0.00% |
| 2020-06-30 | $29.94 Million | +36.12% |
| 2019-12-31 | $21.99 Million | 0.00% |
| 2019-06-30 | $21.99 Million | +42.28% |
| 2018-12-31 | $15.46 Million | 0.00% |
| 2018-06-30 | $15.46 Million | +401.66% |
| 2017-12-31 | $3.08 Million | 0.00% |
| 2017-06-30 | $3.08 Million | +65.10% |
| 2016-06-30 | $1.87 Million | 0.00% |
| 2015-12-31 | $1.87 Million | +469.61% |
| 2015-06-30 | $327.66K | 0.00% |
| 2014-12-31 | $327.66K | +106977.78% |
| 2014-06-30 | $306.00 | 0.00% |
| 2013-12-31 | $306.00 | 0.00% |
| 2013-06-30 | $306.00 | -- |
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more